Immix Biopharma (NASDAQ: IMMX) — Perfil da empresa, notícias e dados financeiros
Immix Biopharma develops innovative oncology treatments to meet unmet medical needs, focusing on clinical advancements in immunotherapy.
Immix Biopharma
Immix Biopharma (NASDAQ:IMMX) is a biotech firm focused on developing and bringing innovative treatments to patients with unmet medical needs, particularly in the oncology and immunotherapy spaces. The company is actively working on several pioneering projects aimed at tackling some of the most challenging diseases by advancing their proprietary platforms and drug candidates through clinical trials. Their objective is to significantly improve patient outcomes by harnessing the power of cutting-edge science and targeted therapies. Through strategic partnerships and rigorous research and development efforts, Immix Biopharma strives to emerge as a key player in transforming the landscape of modern medicine and healthcare.
Resumo
Operações
Produtos e/ou serviços de Immix Biopharma
- Imx-110: First-in-class therapeutic for solid tumors, utilizing a novel approach to target cancer.
- Nanoparticle albumin-bound (nab) technology: Enhances delivery of chemotherapy drugs to improve cancer treatment effectiveness.
- Imx-120: Innovative project focused on developing treatments for rare and difficult-to-treat cancers.
- Collaborations with academic institutions: Partnerships to accelerate drug discovery and development processes.
equipe executiva do Immix Biopharma
- Ilya RachmanCo-Founder, CEO, Chief Scientific Officer & Chairman
- Gabriel MorrisPresident, CFO & Director
- Vladimir P. TorchilinScientific Co-Founder
- Graham RossChief Medical Officer & Head of Clinical Development
- David MarksChief Medical Officer of Cell Therapy
- Mel Davis-PickettHead of CMC Technical Development
- Michael A. GrabowChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Immix Biopharma, em USD.
- Cap. de mercado
- 667,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -30 mi | -29,4 mi | |
| 0 | -22,7 mi | -21,6 mi | |
| 0 | -16,1 mi | -15,4 mi | |
| -89,5 mi | -8,2 mi | -8,2 mi |